Abstract: In some implementations, an expert system may receive, from a user device, a data structure representing a project associated with a technical request. The expert system may map the data structure to a graph representation of a user space to determine a set of users. The expert system may determine a set of statuses, corresponding to the set of users, associated with availability of the set of users. The expert system may transmit, to the user device, instructions for a user interface including visual indicators for the set of users and the set of statuses. The expert system may receive, from the user device, an indication of a selected user from the set of users and may transmit a message addressed to the selected user.

Abstract: The present disclosure relates to IL 12 receptor agonists with improved therapeutic profiles.

Abstract: The present disclosure describes an electronic device. The electronic device includes a memory and a processor. The processor is configured to provide an utterance to an NLU model, which selects an intent from the list of intents based on the utterance. The processor is also configured to cause a response to the utterance to be provided to a user based on the selected intent. The NLU may be trained by obtaining a dataset comprising one or more words, generating a list of intents based at least in part on the dataset, grouping the list of intents into one or more domains, generating a list of training utterances for each intent in the list of intents, and modifying one or more parameters of the NLU model based on the list of intents, the list of training utterances, and/or the one or more domains.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R?. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

Abstract: The present disclosure relates to a composition that includes a poly(hydroxy)urethane (PHU) foam, a phase change material (PCM), and a solid additive, where the PHU foam includes a plurality of voids, at least a portion of the voids contain the PCM and the solid additive, and the composition is capable of being repeatedly cycled through a temperature range, resulting in the PCM cycling between a solid phase and a liquid phase. In some embodiments of the present disclosure, the PCM may include at least one of a hydrated salt, a paraffin wax, a sugar alcohol, a fatty acid, and/or a eutectic mixture.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: The present disclosure relates to IL12 receptor agonists with improved therapeutic profiles.

Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

Abstract: A top of stack mounting component. The top of stack mounting component includes a side portion, the side portion being configured to be mounted to a side of a rack; and, an information handling system retention member, the information handing system retention member preventing upward movement of an information handling system as the information handling system is removed from the rack and passes a potential tipping point where more weight of the information handling system is out of the rack as compared to the portion of the weight of the information handling system which is within the rack.

Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.

Abstract: The present disclosure provides antibody capture complexes and methods of capturing a target antibody secreted by an antibody secreting cell.